Skip to main content
Erschienen in: The International Journal of Cardiovascular Imaging 8/2020

30.04.2020 | Original Paper

Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography

verfasst von: M. P. Huitema, A. L. M. Bakker, J. J. Mager, R. J. Snijder, B. J. W. M. Rensing, M. J. Swaans, J. C. Grutters, M. C. Post

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary hypertension (PH) is a well-recognised complication of sarcoidosis. Non-invasive diagnosis is challenging due to limited accuracy of echocardiography in interstitial lung disease. This study evaluates the value of echocardiographic PH probability for diagnosing PH in pulmonary sarcoidosis. All consecutive patients between August 2015 and November 2018 were prospectively screened for PH, and classified as low, intermediate or high PH probability. Patients with intermediate or high PH probability were referred for right heart catheterisation. PH was defined as a mean pulmonary artery pressure of ≥ 25 mm Hg. Additional data on pulmonary function and chest-CT was collected. Of all 479 patients, PH was present in 17 and absent in 19 patients. Six patients refused right heart catheterisation. PH was present in 33% and 75% of patients with intermediate and high PH probability respectively (n = 36). TRV max was measurable in 46% of all patients. Measurability did not correlate with FVC% predicted or presence of significant fibrosis. In intermediate and high PH probability, TRV max < 2.9 m/s successfully ruled out PH whereas a TRV max > 3.4 confirmed PH in all patients. If TRV max was absent or in between 2.9 and 3.4, secondary echocardiographic signs were not able to improve the diagnostic accuracy. PH is unlikely in patients with a TRV max < 2.9 m/s on echocardiography, whereas PH is highly suspected in a TRV max > 3.4 m/s. Discrimination is challenging if the TRV max is between 2.9–3.4 m/s or absent. Additional secondary signs do not improve discrimination. Decision making for further investigations should be made by an expert team.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU (2018) Pulmonary sarcoidosis. Lancet Respir Med 6:389–402CrossRef Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU (2018) Pulmonary sarcoidosis. Lancet Respir Med 6:389–402CrossRef
2.
Zurück zum Zitat Huitema MP, Grutters JC, Rensing BJ, Reesink HJ, Post MC (2016) Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 24:390–399CrossRef Huitema MP, Grutters JC, Rensing BJ, Reesink HJ, Post MC (2016) Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 24:390–399CrossRef
3.
Zurück zum Zitat Handa T, Nagai S, Miki S et al (2006) Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129:1246–1252CrossRef Handa T, Nagai S, Miki S et al (2006) Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129:1246–1252CrossRef
4.
Zurück zum Zitat Bourbonnais JM, Samavati L (2008) Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 32:296–302CrossRef Bourbonnais JM, Samavati L (2008) Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 32:296–302CrossRef
5.
Zurück zum Zitat Huitema M, Bakker A, Mager J, et al. (2019) Prevalence of pulmonary hypertension in pulmonary sarcoidosis; the first large European prospective study Eur Respir J Huitema M, Bakker A, Mager J, et al. (2019) Prevalence of pulmonary hypertension in pulmonary sarcoidosis; the first large European prospective study Eur Respir J
6.
Zurück zum Zitat Nunes H, Humbert M, Capron F et al (2006) Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61:68–74CrossRef Nunes H, Humbert M, Capron F et al (2006) Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61:68–74CrossRef
7.
Zurück zum Zitat Authors/Task Force Members, Galie N, Humbert M, et al. (2015) ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J Authors/Task Force Members, Galie N, Humbert M, et al. (2015) ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J
8.
Zurück zum Zitat Arcasoy SM, Christie JD, Ferrari VA et al (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167:735–740CrossRef Arcasoy SM, Christie JD, Ferrari VA et al (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167:735–740CrossRef
9.
Zurück zum Zitat Nathan SD. Pulmonary hypertension in interstitial lung disease. International journal of clinical practice Supplement 2008:21–8. Nathan SD. Pulmonary hypertension in interstitial lung disease. International journal of clinical practice Supplement 2008:21–8.
10.
Zurück zum Zitat Miller MR, Crapo R, Hankinson J et al (2005) General considerations for lung function testing. Eur Respir J 26:153–161CrossRef Miller MR, Crapo R, Hankinson J et al (2005) General considerations for lung function testing. Eur Respir J 26:153–161CrossRef
11.
Zurück zum Zitat Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. Br Med J 2:1165–1172CrossRef Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. Br Med J 2:1165–1172CrossRef
12.
Zurück zum Zitat Amsallem M, Sternbach JM, Adigopula S et al (2016) Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr 29:93–102CrossRef Amsallem M, Sternbach JM, Adigopula S et al (2016) Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr 29:93–102CrossRef
13.
Zurück zum Zitat Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713 quiz 786-8 CrossRef Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713 quiz 786-8 CrossRef
14.
Zurück zum Zitat Kovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34:888–894CrossRef Kovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34:888–894CrossRef
15.
Zurück zum Zitat Amsallem M, Boulate D, Kooreman Z et al (2017) Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. Int J Cardiovasc Imaging 33:825–835CrossRef Amsallem M, Boulate D, Kooreman Z et al (2017) Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. Int J Cardiovasc Imaging 33:825–835CrossRef
16.
Zurück zum Zitat Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662CrossRef Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662CrossRef
17.
Zurück zum Zitat Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E (1985) Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 6:359–365CrossRef Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E (1985) Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 6:359–365CrossRef
18.
Zurück zum Zitat Currie PJ, Seward JB, Chan KL et al (1985) Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6:750–756CrossRef Currie PJ, Seward JB, Chan KL et al (1985) Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6:750–756CrossRef
19.
Zurück zum Zitat Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621CrossRef Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621CrossRef
20.
Zurück zum Zitat Keir GJ, Wort SJ, Kokosi M et al (2018) Pulmonary hypertension in interstitial lung disease: limitations of echocardiography compared to cardiac catheterization. Respirology 23:687–694CrossRef Keir GJ, Wort SJ, Kokosi M et al (2018) Pulmonary hypertension in interstitial lung disease: limitations of echocardiography compared to cardiac catheterization. Respirology 23:687–694CrossRef
Metadaten
Titel
Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography
verfasst von
M. P. Huitema
A. L. M. Bakker
J. J. Mager
R. J. Snijder
B. J. W. M. Rensing
M. J. Swaans
J. C. Grutters
M. C. Post
Publikationsdatum
30.04.2020
Verlag
Springer Netherlands
Erschienen in
The International Journal of Cardiovascular Imaging / Ausgabe 8/2020
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-020-01859-9

Weitere Artikel der Ausgabe 8/2020

The International Journal of Cardiovascular Imaging 8/2020 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.